Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. Braxia Scientific Corp. is headquartered in Toronto, Ontario.

BRAX

EURONEXT:BRAX

Braxia Scientific Corp.

Last Close

0.01

02/08 18:14

Market Cap

1.42M

Beta: 1.70

PE Ratio

−0.08

PFCF: −0.16

Analysis Not Available